Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares
In a recent transaction on March 20, 2024, Director Rahul Ballal of Enliven Therapeutics Inc (NASDAQ:ELVN) sold 13,278 shares of the company's stock, according to a SEC Filing. The transaction was executed at an average price of $19.16 per share, indicating a total sale amount of $254,409.28.
Enliven Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel therapies for patients with cancer. The company's research and development efforts are dedicated to creating treatments that aim to improve the lives of patients suffering from various types of cancer.
Over the past year, the insider, Rahul Ballal, has sold a total of 13,278 shares of Enliven Therapeutics Inc and has not made any purchases of the stock. The insider's recent sale represents a continuation of this selling trend.
The insider transaction history for Enliven Therapeutics Inc shows a pattern of insider sales over the past year, with 33 insider sells and no insider buys recorded. This could suggest that insiders have been consistently reducing their holdings in the company over the given period.
On the date of the insider's most recent transaction, shares of Enliven Therapeutics Inc were trading at $19.16, giving the company a market capitalization of approximately $764.104 million.
Investors often monitor insider buying and selling trends as an indicator of a company's future performance. However, it is important to consider a wide range of factors when evaluating the potential implications of insider transactions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
